Altimmune, Inc. (ALT) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of Altimmune, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.66HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
MNPR
Monopar Therapeutics Inc.
$78.10HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Total return — ALT vs MNPR
growth of $100 · dividends reinvested · last 7yALT +56.1% (+6.6%/yr)MNPR -40.9% (-7.2%/yr)ALT compounded faster over this window
ALT MNPR
ALT vs MNPR: by the numbers
- •MNPR is the larger company ($523M vs $517M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -296000.00% net margin).
Metrics side by side
Valuation
| Metric | ALT | MNPR |
|---|---|---|
| P/S ratio | 16680.22 | N/A |
| P/B ratio | 1.09 | 4.00 |
Profitability
| Metric | ALT | MNPR |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -230460.98% | 0.00% |
| Net margin | -296000.00% | 0.00% |
| ROE | -19.35% | -13.64% |
| ROIC | -19.47% | -16.89% |
Growth (annualized)
| Metric | ALT | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | N/A |
| Total return CAGR (5Y) | -25.30% | 27.38% |
Frequently asked
- How have ALT and MNPR total returns compared?
- Over the past 5 years, ALT delivered -25.30% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.